Nexviadyme

avalglucosidase alfa · Sanofi B.V.
AUTHORISED IN THE EU

What Nexviadyme is used for

Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid alpha-glucosidase deficiency).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Nexviadyme
Active substance
avalglucosidase alfa
Disease area
Glycogen Storage Disease Type II
Medicine group
Other alimentary tract and metabolism products
ATC code
A16
Marketing authorisation holder
Sanofi B.V.
Authorised in the EU since
2022

Official information

In the USA

Same active substance: Nexviazyme

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Nexviadyme used for?

Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid alpha-glucosidase deficiency).

What is the active substance in Nexviadyme?

Nexviadyme contains avalglucosidase alfa.

Who makes Nexviadyme?

The EU marketing authorisation holder is Sanofi B.V..

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.